Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siegfried Kohler

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Blood|June 28, 2008
Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsetsSiegfried Kohler, Andreas Thiel
Journal of Immunology (Baltimore, Md. : 1950)|May 6, 2008
Comment on "Homeostasis of the naive CD4+ T cell compartment during aging"Andreas Thiel, Siegfried Kohler
The Lancet. Neurology|March 15, 2016
Myasthenia gravis: subgroup classificationsSiegfried Kohler, Mario Losen, Tobias Alexander, et al.
European Heart Journal Open|August 3, 2022
Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathwayFarid Salih, Siegfried Kohler, Linda Schönborn, et al.
BMJ Open|January 31, 2019
Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trialSiegfried Kohler, Stefanie Märschenz, Ulrike Grittner, et al.
European Journal of Immunology|December 6, 2017
S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onsetAndreas Pelz, Hanne Schaffert, Radharani Diallo, et al.
Brain and Behavior|October 27, 2016
Fatigue in myasthenia gravis: risk factors and impact on quality of lifeSarah Hoffmann, Johanna Ramm, Ulrike Grittner, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 31, 2014
Effective treatment with intravenous immunoglobulins reduces autoreactive T-cell response in patients with CIDPJuliane Klehmet, Jos Goehler, Lena Ulm, et al.
European Journal of Immunology|February 14, 2015
IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravisHanne Schaffert, Andreas Pelz, Abhishek Saxena, et al.
Journal of Translational Autoimmunity|August 30, 2021
Calprotectin as potential novel biomarker in myasthenia gravisFrauke Stascheit, Benjamin Hotter, Sarah Hoffmann, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Blood|June 28, 2008
Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsetsSiegfried Kohler, Andreas Thiel
Journal of Immunology (Baltimore, Md. : 1950)|May 6, 2008
Comment on "Homeostasis of the naive CD4+ T cell compartment during aging"Andreas Thiel, Siegfried Kohler
The Lancet. Neurology|March 15, 2016
Myasthenia gravis: subgroup classificationsSiegfried Kohler, Mario Losen, Tobias Alexander, et al.
European Heart Journal Open|August 3, 2022
Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathwayFarid Salih, Siegfried Kohler, Linda Schönborn, et al.
BMJ Open|January 31, 2019
Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trialSiegfried Kohler, Stefanie Märschenz, Ulrike Grittner, et al.
European Journal of Immunology|December 6, 2017
S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onsetAndreas Pelz, Hanne Schaffert, Radharani Diallo, et al.
Brain and Behavior|October 27, 2016
Fatigue in myasthenia gravis: risk factors and impact on quality of lifeSarah Hoffmann, Johanna Ramm, Ulrike Grittner, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 31, 2014
Effective treatment with intravenous immunoglobulins reduces autoreactive T-cell response in patients with CIDPJuliane Klehmet, Jos Goehler, Lena Ulm, et al.
European Journal of Immunology|February 14, 2015
IL-17-producing CD4(+) T cells contribute to the loss of B-cell tolerance in experimental autoimmune myasthenia gravisHanne Schaffert, Andreas Pelz, Abhishek Saxena, et al.
Journal of Translational Autoimmunity|August 30, 2021
Calprotectin as potential novel biomarker in myasthenia gravisFrauke Stascheit, Benjamin Hotter, Sarah Hoffmann, et al.
Pageof 4